Article Text

Download PDFPDF
Aminocaproic acid in haemophilia and in menorrhagia


Normal haemostasis and healing probably depend on the maintenance of a balance between coagulation and fibrinolysis. If in a wound the fibrin plug is improperly formed because of deficient clotting, any measure to prevent its dissolution may discourage bleeding and promote healing. The synthetic antifibrinolytic agent epsilon-aminocaproic acid (EACA; Epsikapron - Kabi) has therefore been given to patients with haemophilia either alone or in conjunction with antihaemophilic globulin (AHG; Factor VIII). Theoretically the drug should help in bleeding from the urinary tract and after dental extraction because it inhibits plasminogen activators present in urine and saliva.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.